Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Fresenius Medical Care AG & Co. KGaA (FME.DE)
Bad Homburg, DE
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.20% | -7.15% | -8.39% | -11.84% | -14.77% | -11.07% | -26.02% | -15.89% | -44.17% | -52.05% | +52.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 7 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 2 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+1.5% Q1'26: -5.5% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+83.6% ★ Q1'26: -17.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+9.5% Q1'26: +12.5% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+9.4% Q1'26: +8.5% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+5.5% Q1'26: +9.6% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%-0.8% ★ Q1'26: -6.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×4.10× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 17 Rev. Ana. 12 EPS Ana. |
Dec 2027 17 Rev. Ana. 12 EPS Ana. |
Dec 2028 11 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 5 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.87B
est: 9.97B (-1.0%)
|
10.43B
est: 10.56B (-1.2%)
|
10.58B
est: 10.80B (-2.0%)
|
13.02B
est: 14.05B (-7.3%)
|
15.31B
est: 15.46B (-0.9%)
|
17.03B
est: 16.93B (+0.6%)
|
17.78B
est: 17.88B (-0.5%)
|
16.55B
est: 16.50B (+0.3%)
|
17.48B
est: 17.48B (0.0%)
|
17.86B
est: 18.04B (-1.0%)
|
17.62B
est: 17.60B (+0.1%)
|
19.40B
est: 19.48B (-0.4%)
|
19.45B
est: 19.42B (+0.2%)
|
19.34B
est: 19.23B (+0.5%)
|
19.63B
est: 19.54B (+0.5%)
|
19.33B
18.85B – 20.62B
-1.1% YoY
|
19.98B
19.52B – 21.74B
+3.4% YoY
|
20.74B
20.66B – 20.81B
+3.8% YoY
|
21.56B
21.04B – 23.23B
+4.0% YoY
|
22.48B
21.94B – 24.23B
+4.3% YoY
|
| EBITDA |
2.08B
est: 1.49B (+39.1%)
|
2.31B
est: 1.48B (+56.5%)
|
2.12B
est: 1.68B (+26.7%)
|
2.42B
est: 1.88B (+28.5%)
|
2.88B
est: 1.62B (+77.6%)
|
3.06B
est: 2.01B (+51.9%)
|
3.06B
est: 2.21B (+38.4%)
|
3.73B
est: 1.91B (+95.1%)
|
3.78B
est: 3.12B (+21.1%)
|
3.83B
est: 2.89B (+32.6%)
|
3.42B
est: 2.97B (+15.2%)
|
3.22B
est: 3.15B (+2.3%)
|
2.93B
est: 3.29B (-10.8%)
|
3.21B
est: 3.27B (-1.8%)
|
3.34B
est: 3.31B (+0.9%)
|
3.27B
3.19B – 3.49B
-1.1% YoY
|
3.38B
3.30B – 3.68B
+3.4% YoY
|
3.51B
3.50B – 3.52B
+3.8% YoY
|
3.65B
3.56B – 3.93B
+4.0% YoY
|
3.81B
3.71B – 4.10B
+4.3% YoY
|
| EBIT |
1.65B
est: 1.61B (+2.3%)
|
1.82B
est: 1.59B (+14.6%)
|
1.66B
est: 1.76B (-5.8%)
|
1.92B
est: 2.19B (-12.2%)
|
2.23B
est: 1.91B (+17.2%)
|
2.47B
est: 2.36B (+4.8%)
|
2.41B
est: 2.53B (-4.6%)
|
3.19B
est: 2.16B (+47.6%)
|
2.23B
est: 3.25B (-31.5%)
|
2.25B
est: 2.37B (-5.3%)
|
1.83B
est: 2.43B (-24.8%)
|
1.58B
est: 2.58B (-38.9%)
|
1.32B
est: 1.60B (-17.5%)
|
1.46B
est: 1.59B (-8.0%)
|
1.84B
est: 1.61B (+14.0%)
|
1.59B
1.55B – 1.70B
-1.1% YoY
|
1.65B
1.61B – 1.79B
+3.4% YoY
|
1.71B
1.70B – 1.72B
+3.8% YoY
|
1.78B
1.74B – 1.92B
+4.0% YoY
|
1.85B
1.81B – 2.00B
+4.3% YoY
|
| Net Income |
826.45M
est: 823.89M (+0.3%)
|
897.39M
est: 821.57M (+9.2%)
|
803.76M
est: 941.13M (-14.6%)
|
859.37M
est: 1.06B (-18.6%)
|
941.19M
est: 879.68M (+7.0%)
|
1.18B
est: 1.06B (+11.7%)
|
1.28B
est: 1.20B (+6.5%)
|
1.98B
est: 1.17B (+69.5%)
|
1.20B
est: 2.12B (-43.5%)
|
1.16B
est: 1.26B (-7.2%)
|
969.31M
est: 1.29B (-24.7%)
|
673.41M
est: 1.37B (-50.7%)
|
499.00M
est: 530.26M (-5.9%)
|
537.91M
est: 866.94M (-38.0%)
|
978.00M
est: 978.37M (0.0%)
|
1.22B
1.10B – 1.34B
+25.1% YoY
|
1.12B
1.10B – 1.61B
-8.4% YoY
|
1.23B
1.07B – 1.74B
+10.0% YoY
|
1.69B
1.64B – 1.86B
+37.3% YoY
|
1.87B
1.81B – 2.06B
+10.3% YoY
|
| SGA |
1.83B
est: 1.77B (+2.9%)
|
1.68B
est: 1.79B (-6.3%)
|
1.73B
est: 1.99B (-13.1%)
|
2.18B
est: 2.64B (-17.6%)
|
2.65B
est: 2.50B (+5.8%)
|
2.90B
est: 3.27B (-11.4%)
|
3.58B
est: 3.28B (+9.2%)
|
2.87B
est: 3.06B (-6.4%)
|
3.06B
est: 2.90B (+5.5%)
|
3.17B
est: 3.07B (+2.9%)
|
3.10B
est: 3.15B (-1.8%)
|
3.17B
est: 3.35B (-5.3%)
|
3.20B
est: 3.19B (+0.3%)
|
3.14B
est: 3.16B (-0.7%)
|
3.03B
est: 3.21B (-5.4%)
|
3.17B
3.09B – 3.38B
-1.1% YoY
|
3.28B
3.20B – 3.57B
+3.4% YoY
|
3.40B
3.39B – 3.42B
+3.8% YoY
|
3.54B
3.45B – 3.81B
+4.0% YoY
|
3.69B
3.60B – 3.98B
+4.3% YoY
|
| EPS |
2.73
est: 2.73 (-0.2%)
|
2.94
est: 2.82 (+4.4%)
|
2.64
est: 2.66 (-0.9%)
|
2.85
est: 3.03 (-6.0%)
|
3.09
est: 3.23 (-4.3%)
|
3.87
est: 3.81 (+1.6%)
|
4.17
est: 3.99 (+4.5%)
|
6.47
est: 4.14 (+56.1%)
|
3.96
est: 4.24 (-6.7%)
|
3.96
est: 4.51 (-12.2%)
|
3.31
est: 3.47 (-4.6%)
|
2.30
est: 2.90 (-20.8%)
|
1.70
est: 1.81 (-5.9%)
|
1.83
est: 2.88 (-36.4%)
|
3.36
est: 3.90 (-13.8%)
|
4.06
3.79 – 4.62
+4.0% YoY
|
4.42
3.76 – 5.54
+8.9% YoY
|
5.00
3.66 – 5.97
+13.2% YoY
|
5.81
5.63 – 6.40
+16.2% YoY
|
6.41
6.21 – 7.06
+10.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S. | 9.1K +— (+0.0%) | 435.4K -45.5K (-9.5%) | 0.00% +0.000 pp | 0.03% -0.006 pp | EUR45.64 -10.7% | 4 qtrs — |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Helen Giza | Chair of Management Board & Chief Executive Officer | 4M | female |
| Craig Cordola FACHE | Chief Executive Officer of Care Delivery & Member of Management Board | 3M | male |
| Joseph E. Turk Jr. | Chief Executive Officer of Care Enablement & Member of Management Board | 3M | male |
| Charles Hugh-Jones | Global Chief Medical Officer & Member of Management Board | 3M | male |
| Martin Fischer | Chief Financial Officer & Member of the Management Board | 2M | male |
| Jorg Haring | Member of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director | 2M | male |
| Joachim Weith | Senior Vice President of Corporate Communications & Governmental Affairs | — | male |
| Glenn Slater | Senior Vice President of Manufacturing and Supply Chain Operations | — | male |
| Dominik Heger | Executive Vice President and Head of Investor Relations, Strategic Development & Communications | — | — |
| Gail-Suzanne Brown | Senior Vice President of Research & Development | — | — |
| Wolfgang Kummerle | Senior Vice President - Quality Management International | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FME.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
